Financial Performance - For the year ending January 31, 2025, the company generated revenue of 2,085,314 in the previous year[165]. - The company's gross margin for the year ending January 31, 2025, was 862,105 in the prior year, primarily due to lower margins on tape sales[165]. - The company incurred a net loss of (0.99) per share, for the year ended January 31, 2025, compared to a loss of (0.69) per share, for the previous year[171]. - Selling, general and administrative expenses increased to 3,773,606 in the previous year, primarily due to higher non-cash compensation and public relations costs[166]. - The company has not generated any revenue from its 4P Therapeutics segment for the year ending January 31, 2025, due to a shift in focus and the winding down of the main contract[165]. - The company anticipates an increase in demand for its products in the subsequent year, despite the decline in gross margin[165]. Research and Development - Research and development expenses for the Aversa Fentanyl product amounted to 1,960,425 in the previous year, reflecting increased labor and material costs[167]. - Research and development costs are expensed as incurred, indicating a focus on innovation and product development[201]. Cash and Working Capital - As of January 31, 2025, the company had cash and cash equivalents of 3,811,420, significantly up from 22,770, respectively, as of January 31, 2024[172]. - As of January 31, 2025, the Company had cash and cash equivalents totaling 3,595,216 was recorded during the year ending January 31, 2025, reducing the value of goodwill and intangible assets[168]. - Goodwill amounted to 5,021,713 as of January 31, 2024, following an impairment charge of 293,038 to its intellectual property during the year ending January 31, 2025[193]. Inventory and Accounts Receivable - As of January 31, 2025, the total inventory was 46,255, finished goods of 149,177, compared to 1,200 and $11,836 for doubtful accounts related to accounts receivable for the years ended January 31, 2025, and 2024, respectively[190]. - The Company maintains allowances for doubtful accounts based on specific identification and historical loss application, reflecting a proactive approach to credit risk management[190]. Accounting Policies - The Company completed necessary changes to its accounting policies and internal controls to comply with lease accounting standards[200]. - The Company recognizes deferred tax assets and liabilities based on the differences between financial statements and tax basis, using enacted tax rates[203]. - The Company applies a straight-line depreciation method for property, plant, and equipment, with useful lives ranging from 3 to 20 years[192].
Nutriband (NTRB) - 2025 Q4 - Annual Report